BNT162b2
E812198
COVID-19 vaccine
Pfizer–BioNTech COVID-19 vaccine
SARS-CoV-2 vaccine
mRNA vaccine
pharmaceutical product
BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
All labels observed (4)
| Label | Occurrences |
|---|---|
| BNT162b2 canonical | 5 |
| Pfizer–BioNTech COVID‑19 vaccine | 2 |
| BNT162b2 COVID-19 vaccine (with team) | 1 |
| BioNTech COVID-19 mRNA vaccine BNT162b2 | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9632093 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: BNT162b2 Context triple: [BioNTech, developed, BNT162b2]
-
A.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
B.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
C.
REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
D.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
E.
Omicron
Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: BNT162b2 Target entity description: BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
-
A.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
B.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
C.
REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
D.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
E.
Omicron
Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
- F. None of above. chosen
Statements (51)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
Pfizer–BioNTech COVID-19 vaccine ⓘ SARS-CoV-2 vaccine ⓘ mRNA vaccine ⓘ pharmaceutical product ⓘ |
| contains | nucleoside-modified mRNA ⓘ |
| deliverySystem | lipid nanoparticle ⓘ |
| encodesProtein |
SARS-CoV-2 S protein
ⓘ
linked to:
SARS-CoV-2 spike glycoprotein
SARS-CoV-2 spike glycoprotein ⓘ |
| encodesRegion | full-length prefusion stabilized spike protein ⓘ |
| hasAgeIndication |
adolescents
ⓘ
adults ⓘ children ⓘ |
| hasAlternativeName |
Comirnaty
ⓘ
Pfizer–BioNTech COVID-19 vaccine ⓘ
linked to:
Comirnaty
|
| hasATCCode | J07BX03 ⓘ |
| hasCommonAdverseEffects |
fatigue
ⓘ
headache ⓘ injection site pain ⓘ myalgia ⓘ |
| hasDeveloper |
BioNTech
ⓘ
Pfizer ⓘ |
| hasDoseInterval | 21 days between first and second dose ⓘ |
| hasDosingSchedule | two-dose primary series ⓘ |
| hasFirstAuthorizationDate | 2020-12-02 ⓘ |
| hasIndication | prevention of COVID-19 in humans ⓘ |
| hasInitialAdultDose | 30 micrograms mRNA ⓘ |
| hasInitialAdultDoseVolume | 0.3 mL ⓘ |
| hasMechanismOfAction |
elicits cellular immune response to SARS-CoV-2 spike protein
ⓘ
induces neutralizing antibodies against SARS-CoV-2 spike protein ⓘ |
| hasPrimaryInjectionSite | deltoid muscle ⓘ |
| hasRareAdverseEffects |
myocarditis
ⓘ
pericarditis ⓘ |
| hasRegulatoryApproval |
Conditional Marketing Authorization by European Medicines Agency
ⓘ
Emergency Use Authorization by U.S. FDA ⓘ WHO Emergency Use Listing ⓘ
linked to:
Emergency Use Listing by WHO
|
| hasReportedEfficacy | approximately 95% efficacy against symptomatic COVID-19 in initial Phase 3 trial ⓘ |
| hasRouteOfAdministration | intramuscular injection ⓘ |
| hasStabilityAfterThawing | limited stability at refrigerator temperatures ⓘ |
| hasStorageRequirement | ultra-low temperature freezing ⓘ |
| hasStorageTemperature | approximately −70 °C ⓘ |
| hasUSBrandName | Comirnaty ⓘ |
| hasUSFDAEUAdate | 2020-12-11 ⓘ |
| hasUSFDALicensureDate | 2021-08-23 ⓘ |
| isCoDevelopedBy |
BioNTech SE
ⓘ
linked to:
BioNTech
Pfizer Inc. ⓘ
linked to:
Pfizer
|
| targetsDisease |
COVID-19
ⓘ
linked to:
COVID-19 pandemic
|
| targetsVirus | SARS-CoV-2 ⓘ |
| vaccinePlatform | mRNA ⓘ |
| wasFirstAuthorizedIn | United Kingdom ⓘ |
| wasKeyTrial | Phase 3 trial NCT04368728 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: BNT162b2 Description of subject: BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
Referenced by (9)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: BNT162b2
linked to: BNT162b2
subject linked to:
Ozlem Tureci – Chief Medical Officer
linked to: BNT162b2
subject linked to:
Ozlem Tureci – Chief Medical Officer
linked to: BNT162b2
subject linked to:
BNTX